Levetiracetam Sandoz (Levetiracetam)

Levetiracetam is an antiepileptic that reduces seizure activity by modulating neuronal excitability.

• Partial‑onset seizures: reduces frequency of focal seizures, improves overall seizure control, and may lessen associated aura symptoms.
• Generalized tonic‑clonic seizures: helps prevent convulsive episodes, lowers seizure severity, and supports better quality of life for patients with generalized epilepsy.
• Myoclonic seizures: decreases myoclonic jerks, reduces seizure burden, and contributes to improved motor function in affected individuals.

• Levetiracetam binds to the synaptic vesicle protein SV2A, a key regulator of neurotransmitter release. This interaction modulates calcium‑dependent vesicle exocytosis, stabilizing neuronal membranes and decreasing hyper‑synchronous firing. By reducing neuronal excitability, the drug diminishes the propagation of epileptic discharges without significant interaction with ion channels or G‑protein‑coupled receptors. The precise downstream pathways remain under investigation, but the net effect is a reduction in the likelihood of seizure initiation and spread.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Dizziness
• Fatigue
• Somnolence
• Headache
• Irritability

Serious or Rare Side Effects

• Severe allergic reactions (e.g., anaphylaxis, angioedema)
• Stevens‑Johnson syndrome or toxic epidermal necrolysis
• Blood dyscrasias such as neutropenia or thrombocytopenia
• Suicidal thoughts or behavior
• Severe skin rash with systemic symptoms
• Multi‑organ hypersensitivity reactions

When prescribing levetiracetam, clinicians should consider several safety precautions to optimize therapy.

• Renal function: assess baseline and adjust dose in renal impairment.
• Discontinuation: avoid abrupt cessation to reduce risk of seizure recurrence.
• Psychiatric history: monitor for mood changes, depression, or suicidal ideation.
• Pregnancy: safety data are limited; weigh risks and benefits before use.
• Concomitant CNS depressants: use caution as combined sedation may increase.
• Store at room temperature: keep in original packaging, protect from moisture and heat.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid)

• Carbamazepine: enzyme induction may lower levetiracetam plasma levels.
• Phenytoin: reduces levetiracetam exposure, potentially decreasing seizure control.
• Phenobarbital: induces metabolism, leading to subtherapeutic concentrations.
• Rifampin: strong inducer that can markedly decrease levetiracetam levels.
• St. John’s wort: herbal inducer that may reduce drug exposure.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: levetiracetam may reduce hormonal efficacy, consider additional contraception.
• Sedatives or alcohol: combined use may enhance CNS depression and drowsiness.
• Antidepressants: possible increase in irritability or behavioral changes.
• Antipsychotics: monitor for additive neuropsychiatric effects.
• Immunosuppressants: observe for altered drug levels, though interaction is less pronounced.